ACRV
Acrivon Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.69
+3.05%Price chart
Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19
Key dataOct 19, 2026
Open$1.65
From 52W high−43.85%
Volume122119.00
Market cap$72.42M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataOct 19, 2026
Open
$1.65
From 52W high
−43.85%
Volume
122119.00
Market cap
$72.42M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.2x
P/E (TTM)
—
RSI (14)
38.2
MomentumView details →
1D Return
+3.05%
YTD Return
−29.46%
SummaryUpdated Jun 1, 2026
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) is a clinical-stage biopharmaceutical company founded in 2018 and headquartered in Watertown, Massachusetts. The company went public in November 2022 and focuses on developing precision oncology medicines using its proprietary proteomics-based platform to identify patients most likely to respond to specific cancer treatments. Acrivon operates in the competitive biotechnology sector, specifically targeting DNA damage response pathways in cancer cells.
Similar companies
Latest newsMore news →
No recent news for ACRV.